|
|
Volumn 3, Issue 11, 2015, Pages 827-
|
|
Getting to the heart of the matter in type 2 diabetes
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANAGLIFLOZIN;
DAPAGLIFLOZIN;
EMPAGLIFLOZIN;
INSULIN DEGLUDEC;
PLACEBO;
ROSIGLITAZONE;
SITAGLIPTIN;
ANTIDIABETIC AGENT;
ALL CAUSE MORTALITY;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR MORTALITY;
CARDIOVASCULAR RISK;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
GLYCEMIC CONTROL;
HEART FAILURE;
HOSPITAL ADMISSION;
HUMAN;
HYPERGLYCEMIA;
MORTALITY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK ASSESSMENT;
TREATMENT OUTCOME;
WEIGHT REDUCTION;
CARDIOVASCULAR DISEASES;
CLINICAL TRIAL (TOPIC);
COMPLICATION;
DIABETES MELLITUS, TYPE 2;
CARDIOVASCULAR DISEASES;
CLINICAL TRIALS AS TOPIC;
DIABETES MELLITUS, TYPE 2;
HUMANS;
HYPOGLYCEMIC AGENTS;
TREATMENT OUTCOME;
|
|
EID: 84944901432
PISSN: 22138587
EISSN: 22138595
Source Type: Journal
DOI: 10.1016/S2213-8587(15)00384-8 Document Type: Editorial |
|
Times cited : (7)
|
|
References (0)
|